Eli Lilly’s obesity drug beats rival in head-to-head trial — where Cramer sees shares going next
New trial data has cemented Club holding Eli Lilly ‘s pole position in the highly competitive obesity drug race. The news Eli Lilly’s obesity drugContinue Reading